Two New Experts Join the Diaceutics Advisory Panel
08 Septiembre 2021 - 8:30AM
Business Wire
- Two further Key Opinion Leaders provide their support for the
Company’s DXRX platform, the world’s first diagnostic
commercialization platform for Precision Medicine
- Diaceutics’ advisory panel of global experts have more than 120
years of collective experience in Precision Medicine testing
- Panel is working with key stakeholders to unlock power of
Precision Medicine and help patients to get timely access to the
treatment they deserve
- Specialists are part of a growing global network built by
Diaceutics to transform the testing ecosystem
Diaceutics PLC
("Diaceutics" or "the Company")
Diaceutics PLC (AIM: DXRX), the diagnostic commercialization
company, announces the addition of two new Key Opinion Leaders to
its Advisory Panel of experts to support and inform the development
of its DXRX platform – the world’s first diagnostic
commercialization platform for Precision Medicine. The new
additions to the panel are Dr. Avi Kulkarni, Senior Vice President,
Global Head of Life Sciences Research & Development at
Cognizant, and Agathe Blanchon-Ehrsam, VP Long-Range Innovation and
Portfolio Development at Danone.
Dr. Avi Kulkarni has over 20 years’ experience in Personalized
Medicine and brings a leadership view that integrates four pillars:
strategy, operational performance, entrepreneurship and scientific
experience and scholarship. Dr Kulkarni previously held management
consultancy roles at IQVIA and Booz & Co, before spending a
decade in the biotechnology industry around Stanford University
helping to build three biotechnology start-ups: CareDx/XDx (CDNA),
Lumen Therapeutics, and Aviir.
His focus is on capabilities-led transformation of life sciences
companies, and he has extensive experience in drug and diagnostics
product development, mergers and acquisitions, and
commercialization processes. He has helped some of the world’s
leading biotechnology companies develop cell and gene therapies,
build Precision Medicine capabilities, and diversify into new
businesses and markets. Dr Kulkarni will advise the Company on its
strategy through execution, including the enablement of its DXRX
platform, providing advice related to positioning, portfolio
prioritization, product planning and business development, as well
as facilitating additional pharma industry introductions.
Agathe Blanchon-Ehrsam, will join the panel as a Strategy
Advisor for the DXRX platform. She brings over 20 years of
strategic consulting experience. Agathe has helped to build brands
and grow organizations with strategic and hands-on experience
across a variety of business situations – from vision setting,
strategy definition and leadership team facilitation, to complex
team management, marketing campaign design and KPI
optimization.
Previously, Blanchon-Ehrsam was a founding board member of Hot
Bread Kitchen, a nonprofit organization which developed incubation
programs for start-up food entrepreneurs. Long-term engagements for
Casa Cuervo Tequilas, Nestle, and Siemens have further developed
her deep international understanding of industry dynamics and
consumer behavior.
Dr. Avi Kulkarni, Senior Vice President, Global Head of Life
Sciences Research & Development at Cognizant said: “For
decades I have built strategies and helped enable Rx and Dx
companies in their biomarker-based transformations. As the world’s
first diagnostic commercialization platform for Precision Medicine,
the DXRX platform is already making a significant difference in how
data is used and will positively impact how patients are treated.
I’m looking forward to helping Diaceutics further develop the DXRX
platform and continue the progress made to date.”
Agathe Blanchon-Ehrsam, VP Long-Range Innovation and
Portfolio Development at Danone said: “Accelerating cancer
research and improving patient outcomes is one of the big
challenges of our generation. Solving it will require the entire
healthcare ecosystem to work together. DXRX is already changing how
data is used, how partners collaborate and how patients are
treated. I’m excited about the potential for platform business
strategy to further unlock connections and enable the move from
siloed solutions to more powerful, value-creating, and personalized
answers.”
Peter Keeling, CEO and Founder of Diaceutics PLC,
commented:
“We are delighted to welcome two further experts to our network.
As part of our dynamic group of advisors, Avi and Agathe will help
to guide our DXRX platform’s service offering and enhance the value
we deliver to pharma companies, laboratories and diagnostic
companies. In turn, this will help to overcome the obstacles
currently present in the field of Precision Medicine and, more
importantly, greatly benefit patients by getting them access to the
right treatment at the right time.”
Currently, the panel consists of Keith Kerr from Aberdeen
University School of Medicine in Scotland (Professor, Consultant
Pathologist), US-based Kenneth J. Bloom of Invicro and Ambry
Genetics (CMO, MD, FCAP), Markus Eckstein from University Hospital
Erlangen in Germany (MD) and Dr Anthony Magliocco of Protean
BioDiagnostics Inc. (Founder and CEO, Consultant Pathologist) in
the USA.
To date, the panel has undertaken extensive research into the
inefficiencies in Precision Medicine testing which are preventing
patients from getting the treatment they need, when they need it.
For example, the Diaceutics study discussing the impact of COVID-19
on cancer diagnosis, which was accepted as an abstract at the
prestigious 2021 American Society of Clinical Oncology (ASCO)
Annual Meeting, demonstrates from the data that there was a
significant decline in patients presenting to their primary care
physicians with suspicion of cancer for diagnostic investigation
linked to COVID-19 prevention strategies. As a result, it is
predicted that these patients may subsequently present with a more
advanced cancer. Keith Kerr, Professor of Pulmonary Pathology,
Aberdeen Royal Infirmary and Advisor at Diaceutics. was an author
on this abstract.
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of Precision Medicine diagnostics enabled by DXRX - The
Diagnostic Network®.
DXRX is the world's first diagnostic commercialization platform
for Precision Medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005763/en/
Enquiries: Alma PR Caroline Forde Robyn Fisher
Kieran Breheny Matthew Young +44 (0)20 3405 0205
diacuetics@almapr.co.uk
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Diaceutics (LSE:DXRX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024